Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These
populations have an underlying predisposition to deficient insulin secretion, which has a key …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering
agents. Apart from their glucose-lowering effects, large clinical trials assessing certain …

Guidelines RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2
Diabetes Mellitus 2020Table. No title available.

Abstract Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a relatively newer class of
anti-hyperglycemic medications that reduce blood glucose by inhibition of renal glucose re …

Abstract The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized
for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio …

Aims This study aimed to determine the effects of sodium‐glucose cotransporter‐2 inhibitor
(SGLT2i) in heart failure with reduced ejection fraction (HFrEF), compare the effect of …

Background and aims Blood glucose measurement is central to the diagnosis and
management of patients with diabetes. Considering that a clinician relies heavily on blood …

Introduction This study compared efficacy and safety of triple drug fixed-dose combination
(FDC) of dapagliflozin (DAPA)+ sitagliptin (SITA)+ metformin (MET) extended release (ER) …

In this paper, we aim to evaluate the efficacy of antidiabetic cardioprotective molecules such
as Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 …

Background Several clinical trials of dapagliflozin in patients with type 2 diabetes mellitus
(T2DM) at elevated cardiovascular risk have observed reduced hospitalization for heart …